MP52-04 2-YEAR FOLLOW-UP OF RADIUM-223 RE-TREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES | Zendy

AI Assistant Blog Pricing

MP52-04 2-YEAR FOLLOW-UP OF RADIUM-223 RE-TREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.